Final results of a prospective, multicentre, randomized trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma (HD2000 trial)

被引：0
|
作者：
McClanahan, F. [1 ]
Hielscher, T. [2 ]
Rieger, M. [1 ]
Hensel, M. [3 ]
Bentz, M. [4 ]
Schmidt-Wolf, I [5 ]
Kaebisch, A. [6 ]
Salwender, H. [7 ]
Duerk, H. [8 ]
Staiger, H. [9 ]
Mandel, T. [10 ]
Neben, K. [1 ]
Hillengass, J. [1 ]
Ho, A. D. [1 ]
Witzens-Harig, M. [1 ]
机构：
[1] Univ Heidelberg, Heidelberg, Germany
[2] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[3] Onkol Schwerpunkt Praxis, Mannheim, Germany
[4] Stadtkrankenhaus Karlsruhe, Karlsruhe, Germany
[5] Univ Hosp Bonn, Bonn, Germany
[6] Facharztpraxis Innere Med, Giessen, Germany
[7] Asklepios Klin Altona, Hamburg, Germany
[8] St Marien Krankenhaus, Hamm, Germany
[9] Klinikum Mittelbaden, Baden Baden, Germany
[10] SLK Klin Heilbronn, Bad Friedrichshall, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 37 条
  • [31] Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immumocytoma (LP-IC) -: Results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG).
    Buske, C
    Dreyling, MH
    Eimermacher, H
    Boeck, HP
    Pfreundschuh, M
    Metzner, B
    Fuchs, R
    Woermann, B
    Truemper, LH
    Hess, G
    Wandt, H
    Ludwig, WD
    Kreuser, ED
    Schimke, J
    Weh, HJ
    Schmitz, S
    Schmiegel, W
    Unterhalt, M
    Hiddemann, W
    BLOOD, 2004, 104 (11) : 50A - 50A
  • [32] Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
    Pecorelli, Sergio
    Favalli, Giuseppe
    Gadducci, Angiolo
    Katsaros, Dionyssios
    Panici, Pierluigi Benedetti
    Carpi, Amalia
    Scambia, Giovanni
    Ballardini, Michela
    Nanni, Oriana
    Conte, PierFranco
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4642 - 4648
  • [33] A RANDOMIZED MULTICENTRE PHASE III STUDY FOR FIRST LINE TREATMENT OF YOUNG PATIENTS WITH HIGH RISK (AAIPI 2-3) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RITUXIMAB (R) PLUS DOSE-DENSE CHEMOTHERAPY CHOP14/MEGACHOP14 WITH OR WITHOUT INTENSIFIED HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). RESULTS OF DLCL04 TRIAL OF ITALIAN LYMPHOMA FOUNDATION (FIL)
    Vitolo, U.
    Chiappella, A.
    Brusamolino, E.
    Angelucci, E.
    Balzarotti, M.
    Carella, A. M.
    Ciccone, G.
    Gaidano, G.
    Merli, F.
    Pane, F.
    Pavone, V.
    Rossi, G.
    Rigacci, L.
    Stelitano, C.
    Zaja, F.
    Martelli, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 106 - 106
  • [34] Early Versus Late Intensification for Patients With High-Risk Hodgkin Lymphoma-3 Cycles of Intensive Chemotherapy Plus Low-Dose Lymph Node Radiation Therapy Versus 4 Cycles of Combined Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Myeloablative Chemotherapy With Autologous Stem Cell Transplantation Five-Year Results of a Randomized Trial on Behalf of the GOELAMS Group
    Arakelyan, Nina
    Berthou, Christian
    Desablens, Bernard
    de Guibert, Sophie
    Delwail, Vincent
    Moles, Marie-Pierre
    Quittet, Philippe
    Jais, Jean-Philippe
    Colonna, Pierre
    Andrieu, Jean-Marie
    CANCER, 2008, 113 (12) : 3323 - 3330
  • [35] CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596)
    Han Tang
    Lijie Tan
    Yaxing Shen
    Hao Wang
    Miao Lin
    Mingxiang Feng
    Songtao Xu
    Weigang Guo
    Cheng Qian
    Tianshu Liu
    Zhaochong Zeng
    Yingyong Hou
    Zhentao Yu
    Hongjing Jiang
    Zhigang Li
    Chun Chen
    Changhong Lian
    Ming Du
    Hecheng Li
    Deyao Xie
    Jun Yin
    Naiqing Zhao
    Qun Wang
    BMC Cancer, 17
  • [36] CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596)
    Tang, Han
    Tan, Lijie
    Shen, Yaxing
    Wang, Hao
    Lin, Miao
    Feng, Mingxiang
    Xu, Songtao
    Guo, Weigang
    Qian, Cheng
    Liu, Tianshu
    Zeng, Zhaochong
    Hou, Yingyong
    Yu, Zhentao
    Jiang, Hongjing
    Li, Zhigang
    Chen, Chun
    Lian, Changhong
    Du, Ming
    Li, Hecheng
    Xie, Deyao
    Yin, Jun
    Zhao, Naiqing
    Wang, Qun
    BMC CANCER, 2017, 17
  • [37] Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft:: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial.
    Tarella, Corrado
    Zanni, Manuela
    Di Nicola, Massimo
    Patti, Caterina
    Castellino, Claudia
    Crocchiolo, Roberto
    Zoli, Valerio
    Caracciolo, Daniele
    Magni, Michele
    Boccadoro, Mario
    Ciceri, Fabio
    Corradini, Paolo
    Gallamini, Andrea
    Majolino, Ignazio
    Mirto, Salvo
    Gianni, Alessandro M.
    BLOOD, 2007, 110 (11) : 559A - 560A
1234